HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule

• 129 of 240 participants dosed in Regimen I of the HEALEY ALS Platform Trial
• Achievement follows recent expansion of Regimen I from 160 to 240 participants
• Recruitment and dosing momentum continues to exceed expectations

Neurizon Therapeutics Limited (ASX: NUZ) announced that the HEALEY ALS Platform Trial evaluating NUZ-001 for ALS treatment has surpassed a 50% dosing milestone, with 129 out of 240 participants dosed in Regimen I. This achievement follows the expansion of Regimen I from 160 to 240 participants, aiming for a larger and more informative dataset. As of June 9, 2026, 167 participants have been assigned to Regimen I, with 78 clinical trial sites activated in the US. The milestone highlights the operational strength and efficiency of the trial network and strong engagement from the ALS community.

Last participant dosing in Q2 CY2027, topline results in early Q3 CY2027

Neurizon remains well positioned to deliver a robust dataset to support future regulatory, partnering, and commercial opportunities for NUZ-001.